{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:00:50Z","timestamp":1760061650328},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T00:00:00Z","timestamp":1347321600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1745-6215-13-162","type":"journal-article","created":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T01:10:49Z","timestamp":1347412249000},"source":"Crossref","is-referenced-by-count":8,"title":["Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)"],"prefix":"10.1186","volume":"13","author":[{"given":"Michal M","family":"Farkowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Maciag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Pytkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Szwed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,11]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder I, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31: 2369-2429. Erratum in: Eur Heart J 2011, 32:1172","journal-title":"Eur Heart J"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le-Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC, Priori SG, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA: 2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation\/American Heart association task force on practice guidelines. Circulation. 2011, 123: e269-e367. 10.1161\/CIR.0b013e318214876d.","journal-title":"Circulation"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.amjcard.2010.06.054","volume":"106","author":"CM Pratt","year":"2010","unstructured":"Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH: Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010, 106: 1277-1283. 10.1016\/j.amjcard.2010.06.054.","journal-title":"Am J Cardiol"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2004.09.021","volume":"44","author":"D Roy","year":"2004","unstructured":"Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, Lee J, Vidaillet H, Dickinson G, Grant S, Ezrin AM, Beatch GN: CRAFT Investigators: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004, 44: 2355-2361. 10.1016\/j.jacc.2004.09.021.","journal-title":"J Am Coll Cardiol"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.107.723866","volume":"117","author":"D Roy","year":"2008","unstructured":"Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ: Atrial Arrhythmia Conversion Trial Investigators: Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008, 117: 1518-1525. 10.1161\/CIRCULATIONAHA.107.723866.","journal-title":"Circulation"},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ahj.2010.02.035","volume":"159","author":"IG Stiell","year":"2010","unstructured":"Stiell IG, Roos JS, Kavanagh KM, Dickinson G: A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010, 159: 1095-1101. 10.1016\/j.ahj.2010.02.035.","journal-title":"Am Heart J"},{"key":"1095_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/0002-9149(62)90075-9","volume":"9","author":"SR Kline","year":"1962","unstructured":"Kline SR, Dreifus LS, Watanabe Y, McGarry TF, Likoff W: Evaluation of the antiarrhythmic properties of antazoline. A preliminary study. Am J Cardiol. 1962, 9: 564-567. 10.1016\/0002-9149(62)90075-9.","journal-title":"Am J Cardiol"},{"key":"1095_CR8","first-page":"924","volume":"45","author":"M Srzednicki","year":"1990","unstructured":"Srzednicki M, Sadowski Z, Kulikowski A: Evaluation of the anti-arrhythmia effectiveness of Phenazolinum Polfa in paroxysmal atrial fibrillation. Pol Tyg Lek. 1990, 45: 924-927.","journal-title":"Pol Tyg Lek"},{"key":"1095_CR9","first-page":"3","volume":"2","author":"B Tarchalska-Kry\u0144ska","year":"1997","unstructured":"Tarchalska-Kry\u0144ska B: Nowe generacje lek\u00f3w przeciwhistaminowych stosowanych w terapii chor\u00f3b alergicznych. Alergia Astma Immunologia. 1997, 2: 3-8.","journal-title":"Alergia Astma Immunologia"},{"key":"1095_CR10","first-page":"121","volume":"18","author":"A Cieslinski","year":"1975","unstructured":"Cieslinski A: Clinical evaluation of antistin in the treatment of arrhythmia. Kardiol Pol. 1975, 18: 121-128.","journal-title":"Kardiol Pol"},{"key":"1095_CR11","first-page":"391","volume":"113","author":"E Downar","year":"1975","unstructured":"Downar E, Waxman MB: Antazoline therapy of recurrent refractory supraventricular arrhythmias\u2013a preliminary report. Can Med Assoc J. 1975, 113: 391-393.","journal-title":"Can Med Assoc J"},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/000331977002100104","volume":"21","author":"DA Gehring","year":"1970","unstructured":"Gehring DA, Kehler JG: Conversion of atrial fibrillation with antazoline hydrochloride (Arithmin). Angiology. 1970, 21: 11-17. 10.1177\/000331977002100104.","journal-title":"Angiology"},{"key":"1095_CR13","first-page":"326","volume":"28","author":"A Georgopoulos","year":"1969","unstructured":"Georgopoulos A, Kyriakou K, Marselos A, Tountas C: The antifibrillatory effects of antazoline. Bull Soc Int Chir. 1969, 28: 326-331.","journal-title":"Bull Soc Int Chir"},{"key":"1095_CR14","first-page":"2877","volume":"139","author":"S Haunso","year":"1977","unstructured":"Haunso S, Eliasen P, Berning J, Rasmussen V, Pedersen JF, Skagen K: Comparison between antazoline and verapamil in the treatment of paroxysmal supraventricular tachycardia. Ugeskr Laeger. 1977, 139: 2877-2879.","journal-title":"Ugeskr Laeger"},{"key":"1095_CR15","first-page":"145","volume":"116","author":"GR Herrmann","year":"1964","unstructured":"Herrmann GR, Secrest CR, Vilbig GJ, Uintra , Herrmann AW: Antiarrhythmic and Antifibrillary Antazoline: a clinical study. J La State Med Soc. 1964, 116: 145-158.","journal-title":"J La State Med Soc"},{"key":"1095_CR16","first-page":"376","volume":"54","author":"AM Higazi","year":"1971","unstructured":"Higazi AM, el-Ahmdai LM, Ageeb M: The antiarrythmic action of antazoline (an experimental study). J Egypt Med Assoc. 1971, 54: 376-384.","journal-title":"J Egypt Med Assoc"},{"key":"1095_CR17","first-page":"113","volume":"22","author":"E Kabela","year":"1967","unstructured":"Kabela E, Mena MA, Martinez-Lopez M, Mendez R: The action of the antihistaminic agents antazoline and meclizine on experimental arrhythmias. Acta Cardiol. 1967, 22: 113-127.","journal-title":"Acta Cardiol"},{"key":"1095_CR18","first-page":"41","volume":"60","author":"RG Kiger","year":"1964","unstructured":"Kiger RG: An evaluation of antazoline as an anti-arrhythmic agent. J S C Med Assoc. 1964, 60: 41-44.","journal-title":"J S C Med Assoc"},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0002-9149(63)90084-5","volume":"11","author":"L Leon-Sotomayor","year":"1963","unstructured":"Leon-Sotomayor L: A clinical evaluation of the antiarrhythmic properties of antazoline. Am J Cardiol. 1963, 11: 646-653. 10.1016\/0002-9149(63)90084-5.","journal-title":"Am J Cardiol"},{"key":"1095_CR20","first-page":"538","volume":"65","author":"EM Malone","year":"1964","unstructured":"Malone EM, Stoffer RP, Pokorny C: The irregular heart. Antazoline in cardiac arrhythmias and its side effects. J Kans Med Soc. 1964, 65: 538-540.","journal-title":"J Kans Med Soc"},{"key":"1095_CR21","first-page":"97","volume":"50","author":"M Muniz","year":"1965","unstructured":"Muniz M, Bellini AJ: Treatment of paroxysmal tachycardias. Our experience with antazoline. Folha Med. 1965, 50: 97-118.","journal-title":"Folha Med"},{"key":"1095_CR22","first-page":"525","volume":"31","author":"H Ogan","year":"1965","unstructured":"Ogan H, Oran E, Ozbay G: Antazoline (Antistine) as an Antiarrythmic Agent. Turk Tip Cemiy Mecm. 1965, 31: 525-536.","journal-title":"Turk Tip Cemiy Mecm"},{"key":"1095_CR23","first-page":"303","volume":"17","author":"U Pasini","year":"1964","unstructured":"Pasini U, Carvalhofilho ET, Giuliano H, Vargaftig BB, Pileggi F, Decourt LV: The use of antazoline in the treatment of cardiac arrhytmias. Clinical study. Arq Bras Cardiol. 1964, 17: 303-312.","journal-title":"Arq Bras Cardiol"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/0002-9149(64)90035-9","volume":"14","author":"EW Reynolds","year":"1964","unstructured":"Reynolds EW, Baird WM, Clifford ME: A clinical trial of antazoline in the treatment of arrhythmias. Am J Cardiol. 1964, 14: 513-521. 10.1016\/0002-9149(64)90035-9.","journal-title":"Am J Cardiol"},{"key":"1095_CR25","first-page":"102","volume":"39","author":"JA Ruiperez","year":"1969","unstructured":"Ruiperez JA, Hermosillo JA, Marquez J, Brenes C, Osatinsky M, Cardenas M: Prevention of arrhythmias due to cardioversion using antazoline. Arch Inst Cardiol Mex. 1969, 39: 102-113.","journal-title":"Arch Inst Cardiol Mex"},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/pgmj.48.559.304","volume":"48","author":"SS Shah","year":"1972","unstructured":"Shah SS, Vaidya CH, Doshi HV: Antazoline in the treatment of cardiac arrhythmias. Postgrad Med J. 1972, 48: 304-307. 10.1136\/pgmj.48.559.304.","journal-title":"Postgrad Med J"},{"key":"1095_CR27","first-page":"363","volume":"19","author":"HV Srinivas","year":"1971","unstructured":"Srinivas HV, Antani JA: Experience in conversion of cardiac arrhythmia with antazoline (antistin R). J Assoc Physicians India. 1971, 19: 363-368.","journal-title":"J Assoc Physicians India"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-13-162\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-13-162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T14:16:31Z","timestamp":1467814591000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-13-162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-13-162","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,11]]},"article-number":"162"}}